nodes	percent_of_prediction	percent_of_DWPC	metapath
Alfuzosin—Angioedema—Lisinopril—systemic scleroderma	0.0015	0.0015	CcSEcCtD
Alfuzosin—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.0015	0.0015	CcSEcCtD
Alfuzosin—Abdominal pain—Captopril—systemic scleroderma	0.0015	0.0015	CcSEcCtD
Alfuzosin—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00149	0.00149	CcSEcCtD
Alfuzosin—Oedema—Mycophenolic acid—systemic scleroderma	0.00149	0.00149	CcSEcCtD
Alfuzosin—Nausea—Pentoxifylline—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Alfuzosin—Malaise—Lisinopril—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Alfuzosin—Infection—Mycophenolic acid—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Alfuzosin—Vertigo—Lisinopril—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Alfuzosin—Diarrhoea—Mometasone—systemic scleroderma	0.00147	0.00147	CcSEcCtD
Alfuzosin—Syncope—Lisinopril—systemic scleroderma	0.00147	0.00147	CcSEcCtD
Alfuzosin—Shock—Mycophenolic acid—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Alfuzosin—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Alfuzosin—Hypotension—Leflunomide—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Alfuzosin—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Alfuzosin—Tachycardia—Mycophenolic acid—systemic scleroderma	0.00145	0.00145	CcSEcCtD
Alfuzosin—Palpitations—Lisinopril—systemic scleroderma	0.00145	0.00145	CcSEcCtD
Alfuzosin—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.00145	0.00145	CcSEcCtD
Alfuzosin—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00145	0.00145	CcSEcCtD
Alfuzosin—Loss of consciousness—Lisinopril—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Alfuzosin—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00143	0.00143	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.00142	0.00142	CcSEcCtD
Alfuzosin—Chest pain—Lisinopril—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Alfuzosin—Arthralgia—Lisinopril—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Alfuzosin—Back pain—Mycophenolate mofetil—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Alfuzosin—Hypotension—Mycophenolic acid—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Alfuzosin—Discomfort—Lisinopril—systemic scleroderma	0.00138	0.00138	CcSEcCtD
Alfuzosin—Dyspepsia—Leflunomide—systemic scleroderma	0.00137	0.00137	CcSEcCtD
Alfuzosin—Vomiting—Mometasone—systemic scleroderma	0.00137	0.00137	CcSEcCtD
Alfuzosin—Dry mouth—Lisinopril—systemic scleroderma	0.00137	0.00137	CcSEcCtD
Alfuzosin—Feeling abnormal—Azathioprine—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Alfuzosin—Rash—Mometasone—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Alfuzosin—Asthenia—Captopril—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Alfuzosin—Dermatitis—Mometasone—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Alfuzosin—Osteoarthritis—Methotrexate—systemic scleroderma	0.00135	0.00135	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00135	0.00135	CcSEcCtD
Alfuzosin—Headache—Mometasone—systemic scleroderma	0.00135	0.00135	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00135	0.00135	CcSEcCtD
Alfuzosin—Fatigue—Leflunomide—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Alfuzosin—Oedema—Lisinopril—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Alfuzosin—Pruritus—Captopril—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Alfuzosin—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Alfuzosin—Constipation—Leflunomide—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Alfuzosin—Pain—Leflunomide—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Alfuzosin—Infection—Lisinopril—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Alfuzosin—Somnolence—Mycophenolic acid—systemic scleroderma	0.00132	0.00132	CcSEcCtD
Alfuzosin—Shock—Lisinopril—systemic scleroderma	0.00132	0.00132	CcSEcCtD
Alfuzosin—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Alfuzosin—Thrombocytopenia—Lisinopril—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Alfuzosin—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Alfuzosin—Tachycardia—Lisinopril—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Alfuzosin—Abdominal pain—Azathioprine—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Alfuzosin—Skin disorder—Lisinopril—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Alfuzosin—Malaise—Mycophenolate mofetil—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Alfuzosin—Hyperhidrosis—Lisinopril—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Alfuzosin—Diarrhoea—Captopril—systemic scleroderma	0.00129	0.00129	CcSEcCtD
Alfuzosin—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.00129	0.00129	CcSEcCtD
Alfuzosin—Syncope—Mycophenolate mofetil—systemic scleroderma	0.00129	0.00129	CcSEcCtD
Alfuzosin—Erectile dysfunction—Prednisone—systemic scleroderma	0.00129	0.00129	CcSEcCtD
Alfuzosin—Feeling abnormal—Leflunomide—systemic scleroderma	0.00129	0.00129	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00128	0.00128	CcSEcCtD
Alfuzosin—Fatigue—Mycophenolic acid—systemic scleroderma	0.00128	0.00128	CcSEcCtD
Alfuzosin—Nausea—Mometasone—systemic scleroderma	0.00128	0.00128	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00128	0.00128	CcSEcCtD
Alfuzosin—Pain—Mycophenolic acid—systemic scleroderma	0.00127	0.00127	CcSEcCtD
Alfuzosin—Constipation—Mycophenolic acid—systemic scleroderma	0.00127	0.00127	CcSEcCtD
Alfuzosin—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.00127	0.00127	CcSEcCtD
Alfuzosin—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Alfuzosin—Hypotension—Lisinopril—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Alfuzosin—Dizziness—Captopril—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Alfuzosin—Urticaria—Leflunomide—systemic scleroderma	0.00124	0.00124	CcSEcCtD
Alfuzosin—Abdominal pain—Leflunomide—systemic scleroderma	0.00123	0.00123	CcSEcCtD
Alfuzosin—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.00123	0.00123	CcSEcCtD
Alfuzosin—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Alfuzosin—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Alfuzosin—Neuropathy peripheral—Prednisone—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Alfuzosin—Breast disorder—Methotrexate—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Alfuzosin—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Alfuzosin—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.00121	0.00121	CcSEcCtD
Alfuzosin—Vomiting—Captopril—systemic scleroderma	0.0012	0.0012	CcSEcCtD
Alfuzosin—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.0012	0.0012	CcSEcCtD
Alfuzosin—Rash—Captopril—systemic scleroderma	0.00119	0.00119	CcSEcCtD
Alfuzosin—Dermatitis—Captopril—systemic scleroderma	0.00119	0.00119	CcSEcCtD
Alfuzosin—Somnolence—Lisinopril—systemic scleroderma	0.00119	0.00119	CcSEcCtD
Alfuzosin—Headache—Captopril—systemic scleroderma	0.00119	0.00119	CcSEcCtD
Alfuzosin—Dyspepsia—Lisinopril—systemic scleroderma	0.00118	0.00118	CcSEcCtD
Alfuzosin—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00118	0.00118	CcSEcCtD
Alfuzosin—Oedema—Mycophenolate mofetil—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Alfuzosin—Infection—Mycophenolate mofetil—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Alfuzosin—Fatigue—Lisinopril—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Alfuzosin—Shock—Mycophenolate mofetil—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Alfuzosin—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Alfuzosin—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Alfuzosin—Constipation—Lisinopril—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Alfuzosin—Pain—Lisinopril—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Alfuzosin—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Alfuzosin—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00114	0.00114	CcSEcCtD
Alfuzosin—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.00114	0.00114	CcSEcCtD
Alfuzosin—Diarrhoea—Azathioprine—systemic scleroderma	0.00113	0.00113	CcSEcCtD
Alfuzosin—Nausea—Captopril—systemic scleroderma	0.00112	0.00112	CcSEcCtD
Alfuzosin—Asthenia—Leflunomide—systemic scleroderma	0.00112	0.00112	CcSEcCtD
Alfuzosin—Feeling abnormal—Lisinopril—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Alfuzosin—Pruritus—Leflunomide—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Alfuzosin—Connective tissue disorder—Prednisone—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Alfuzosin—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Alfuzosin—Dizziness—Azathioprine—systemic scleroderma	0.00109	0.00109	CcSEcCtD
Alfuzosin—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.00109	0.00109	CcSEcCtD
Alfuzosin—Erectile dysfunction—Methotrexate—systemic scleroderma	0.00108	0.00108	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.00107	0.00107	CcSEcCtD
Alfuzosin—Asthenia—Mycophenolic acid—systemic scleroderma	0.00107	0.00107	CcSEcCtD
Alfuzosin—Diarrhoea—Leflunomide—systemic scleroderma	0.00107	0.00107	CcSEcCtD
Alfuzosin—Urticaria—Lisinopril—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Alfuzosin—Abdominal pain—Lisinopril—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Alfuzosin—Pruritus—Mycophenolic acid—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Alfuzosin—Vomiting—Azathioprine—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Alfuzosin—Eye disorder—Prednisone—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Alfuzosin—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.00104	0.00104	CcSEcCtD
Alfuzosin—Infestation NOS—Methotrexate—systemic scleroderma	0.00104	0.00104	CcSEcCtD
Alfuzosin—Infestation—Methotrexate—systemic scleroderma	0.00104	0.00104	CcSEcCtD
Alfuzosin—Drowsiness—Methotrexate—systemic scleroderma	0.00104	0.00104	CcSEcCtD
Alfuzosin—Rash—Azathioprine—systemic scleroderma	0.00104	0.00104	CcSEcCtD
Alfuzosin—Dermatitis—Azathioprine—systemic scleroderma	0.00104	0.00104	CcSEcCtD
Alfuzosin—Flushing—Prednisone—systemic scleroderma	0.00104	0.00104	CcSEcCtD
Alfuzosin—Headache—Azathioprine—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Alfuzosin—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Alfuzosin—Dizziness—Leflunomide—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Alfuzosin—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Alfuzosin—Angiopathy—Prednisone—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Alfuzosin—Constipation—Mycophenolate mofetil—systemic scleroderma	0.001	0.001	CcSEcCtD
Alfuzosin—Pain—Mycophenolate mofetil—systemic scleroderma	0.001	0.001	CcSEcCtD
Alfuzosin—Sweating—Methotrexate—systemic scleroderma	0.001	0.001	CcSEcCtD
Alfuzosin—Vomiting—Leflunomide—systemic scleroderma	0.000992	0.000992	CcSEcCtD
Alfuzosin—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000986	0.000986	CcSEcCtD
Alfuzosin—Dizziness—Mycophenolic acid—systemic scleroderma	0.000984	0.000984	CcSEcCtD
Alfuzosin—Rash—Leflunomide—systemic scleroderma	0.000983	0.000983	CcSEcCtD
Alfuzosin—Dermatitis—Leflunomide—systemic scleroderma	0.000983	0.000983	CcSEcCtD
Alfuzosin—Mental disorder—Prednisone—systemic scleroderma	0.000982	0.000982	CcSEcCtD
Alfuzosin—Nausea—Azathioprine—systemic scleroderma	0.000981	0.000981	CcSEcCtD
Alfuzosin—Headache—Leflunomide—systemic scleroderma	0.000977	0.000977	CcSEcCtD
Alfuzosin—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000968	0.000968	CcSEcCtD
Alfuzosin—Asthenia—Lisinopril—systemic scleroderma	0.000962	0.000962	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00096	0.00096	CcSEcCtD
Alfuzosin—Pruritus—Lisinopril—systemic scleroderma	0.000948	0.000948	CcSEcCtD
Alfuzosin—Vomiting—Mycophenolic acid—systemic scleroderma	0.000946	0.000946	CcSEcCtD
Alfuzosin—Rash—Mycophenolic acid—systemic scleroderma	0.000938	0.000938	CcSEcCtD
Alfuzosin—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000937	0.000937	CcSEcCtD
Alfuzosin—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000933	0.000933	CcSEcCtD
Alfuzosin—Headache—Mycophenolic acid—systemic scleroderma	0.000932	0.000932	CcSEcCtD
Alfuzosin—Pharyngitis—Methotrexate—systemic scleroderma	0.000929	0.000929	CcSEcCtD
Alfuzosin—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000928	0.000928	CcSEcCtD
Alfuzosin—Nausea—Leflunomide—systemic scleroderma	0.000926	0.000926	CcSEcCtD
Alfuzosin—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000925	0.000925	CcSEcCtD
Alfuzosin—Urethral disorder—Methotrexate—systemic scleroderma	0.000918	0.000918	CcSEcCtD
Alfuzosin—Diarrhoea—Lisinopril—systemic scleroderma	0.000917	0.000917	CcSEcCtD
Alfuzosin—Ill-defined disorder—Prednisone—systemic scleroderma	0.000905	0.000905	CcSEcCtD
Alfuzosin—Angioedema—Prednisone—systemic scleroderma	0.000891	0.000891	CcSEcCtD
Alfuzosin—Dizziness—Lisinopril—systemic scleroderma	0.000886	0.000886	CcSEcCtD
Alfuzosin—Nausea—Mycophenolic acid—systemic scleroderma	0.000884	0.000884	CcSEcCtD
Alfuzosin—Malaise—Prednisone—systemic scleroderma	0.00088	0.00088	CcSEcCtD
Alfuzosin—Vertigo—Prednisone—systemic scleroderma	0.000876	0.000876	CcSEcCtD
Alfuzosin—Eye disorder—Methotrexate—systemic scleroderma	0.000875	0.000875	CcSEcCtD
Alfuzosin—Syncope—Prednisone—systemic scleroderma	0.000875	0.000875	CcSEcCtD
Alfuzosin—Cardiac disorder—Methotrexate—systemic scleroderma	0.000869	0.000869	CcSEcCtD
Alfuzosin—Loss of consciousness—Prednisone—systemic scleroderma	0.000857	0.000857	CcSEcCtD
Alfuzosin—Vomiting—Lisinopril—systemic scleroderma	0.000852	0.000852	CcSEcCtD
Alfuzosin—Angiopathy—Methotrexate—systemic scleroderma	0.00085	0.00085	CcSEcCtD
Alfuzosin—Rash—Lisinopril—systemic scleroderma	0.000845	0.000845	CcSEcCtD
Alfuzosin—Dermatitis—Lisinopril—systemic scleroderma	0.000844	0.000844	CcSEcCtD
Alfuzosin—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000844	0.000844	CcSEcCtD
Alfuzosin—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000843	0.000843	CcSEcCtD
Alfuzosin—Headache—Lisinopril—systemic scleroderma	0.00084	0.00084	CcSEcCtD
Alfuzosin—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000831	0.000831	CcSEcCtD
Alfuzosin—Arthralgia—Prednisone—systemic scleroderma	0.00083	0.00083	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000825	0.000825	CcSEcCtD
Alfuzosin—Discomfort—Prednisone—systemic scleroderma	0.00082	0.00082	CcSEcCtD
Alfuzosin—Mental disorder—Methotrexate—systemic scleroderma	0.00082	0.00082	CcSEcCtD
Alfuzosin—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000803	0.000803	CcSEcCtD
Alfuzosin—Nausea—Lisinopril—systemic scleroderma	0.000796	0.000796	CcSEcCtD
Alfuzosin—Oedema—Prednisone—systemic scleroderma	0.000796	0.000796	CcSEcCtD
Alfuzosin—Infection—Prednisone—systemic scleroderma	0.000791	0.000791	CcSEcCtD
Alfuzosin—Back pain—Methotrexate—systemic scleroderma	0.000788	0.000788	CcSEcCtD
Alfuzosin—Shock—Prednisone—systemic scleroderma	0.000783	0.000783	CcSEcCtD
Alfuzosin—Nervous system disorder—Prednisone—systemic scleroderma	0.000781	0.000781	CcSEcCtD
Alfuzosin—Tachycardia—Prednisone—systemic scleroderma	0.000777	0.000777	CcSEcCtD
Alfuzosin—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000777	0.000777	CcSEcCtD
Alfuzosin—Skin disorder—Prednisone—systemic scleroderma	0.000773	0.000773	CcSEcCtD
Alfuzosin—Hyperhidrosis—Prednisone—systemic scleroderma	0.00077	0.00077	CcSEcCtD
Alfuzosin—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000756	0.000756	CcSEcCtD
Alfuzosin—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000747	0.000747	CcSEcCtD
Alfuzosin—Rash—Mycophenolate mofetil—systemic scleroderma	0.00074	0.00074	CcSEcCtD
Alfuzosin—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.00074	0.00074	CcSEcCtD
Alfuzosin—Headache—Mycophenolate mofetil—systemic scleroderma	0.000736	0.000736	CcSEcCtD
Alfuzosin—Malaise—Methotrexate—systemic scleroderma	0.000735	0.000735	CcSEcCtD
Alfuzosin—Vertigo—Methotrexate—systemic scleroderma	0.000732	0.000732	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000725	0.000725	CcSEcCtD
Alfuzosin—Dyspepsia—Prednisone—systemic scleroderma	0.000701	0.000701	CcSEcCtD
Alfuzosin—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000698	0.000698	CcSEcCtD
Alfuzosin—Arthralgia—Methotrexate—systemic scleroderma	0.000694	0.000694	CcSEcCtD
Alfuzosin—Chest pain—Methotrexate—systemic scleroderma	0.000694	0.000694	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000689	0.000689	CcSEcCtD
Alfuzosin—Fatigue—Prednisone—systemic scleroderma	0.000686	0.000686	CcSEcCtD
Alfuzosin—Discomfort—Methotrexate—systemic scleroderma	0.000686	0.000686	CcSEcCtD
Alfuzosin—Constipation—Prednisone—systemic scleroderma	0.000681	0.000681	CcSEcCtD
Alfuzosin—Infection—Methotrexate—systemic scleroderma	0.000661	0.000661	CcSEcCtD
Alfuzosin—Feeling abnormal—Prednisone—systemic scleroderma	0.000656	0.000656	CcSEcCtD
Alfuzosin—Nervous system disorder—Methotrexate—systemic scleroderma	0.000652	0.000652	CcSEcCtD
Alfuzosin—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000651	0.000651	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000651	0.000651	CcSEcCtD
Alfuzosin—Skin disorder—Methotrexate—systemic scleroderma	0.000646	0.000646	CcSEcCtD
Alfuzosin—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000643	0.000643	CcSEcCtD
Alfuzosin—Urticaria—Prednisone—systemic scleroderma	0.000632	0.000632	CcSEcCtD
Alfuzosin—Abdominal pain—Prednisone—systemic scleroderma	0.000629	0.000629	CcSEcCtD
Alfuzosin—Hypotension—Methotrexate—systemic scleroderma	0.000622	0.000622	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000606	0.000606	CcSEcCtD
Alfuzosin—Somnolence—Methotrexate—systemic scleroderma	0.000591	0.000591	CcSEcCtD
Alfuzosin—Dyspepsia—Methotrexate—systemic scleroderma	0.000586	0.000586	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000574	0.000574	CcSEcCtD
Alfuzosin—Fatigue—Methotrexate—systemic scleroderma	0.000574	0.000574	CcSEcCtD
Alfuzosin—Asthenia—Prednisone—systemic scleroderma	0.000571	0.000571	CcSEcCtD
Alfuzosin—Pain—Methotrexate—systemic scleroderma	0.000569	0.000569	CcSEcCtD
Alfuzosin—Pruritus—Prednisone—systemic scleroderma	0.000563	0.000563	CcSEcCtD
Alfuzosin—Feeling abnormal—Methotrexate—systemic scleroderma	0.000548	0.000548	CcSEcCtD
Alfuzosin—Diarrhoea—Prednisone—systemic scleroderma	0.000545	0.000545	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000544	0.000544	CcSEcCtD
Alfuzosin—Urticaria—Methotrexate—systemic scleroderma	0.000528	0.000528	CcSEcCtD
Alfuzosin—Dizziness—Prednisone—systemic scleroderma	0.000526	0.000526	CcSEcCtD
Alfuzosin—Abdominal pain—Methotrexate—systemic scleroderma	0.000526	0.000526	CcSEcCtD
Alfuzosin—Vomiting—Prednisone—systemic scleroderma	0.000506	0.000506	CcSEcCtD
Alfuzosin—Rash—Prednisone—systemic scleroderma	0.000502	0.000502	CcSEcCtD
Alfuzosin—Dermatitis—Prednisone—systemic scleroderma	0.000501	0.000501	CcSEcCtD
Alfuzosin—Headache—Prednisone—systemic scleroderma	0.000499	0.000499	CcSEcCtD
Alfuzosin—Asthenia—Methotrexate—systemic scleroderma	0.000477	0.000477	CcSEcCtD
Alfuzosin—Nausea—Prednisone—systemic scleroderma	0.000473	0.000473	CcSEcCtD
Alfuzosin—Pruritus—Methotrexate—systemic scleroderma	0.000471	0.000471	CcSEcCtD
Alfuzosin—Diarrhoea—Methotrexate—systemic scleroderma	0.000455	0.000455	CcSEcCtD
Alfuzosin—Dizziness—Methotrexate—systemic scleroderma	0.00044	0.00044	CcSEcCtD
Alfuzosin—Vomiting—Methotrexate—systemic scleroderma	0.000423	0.000423	CcSEcCtD
Alfuzosin—Rash—Methotrexate—systemic scleroderma	0.000419	0.000419	CcSEcCtD
Alfuzosin—Dermatitis—Methotrexate—systemic scleroderma	0.000419	0.000419	CcSEcCtD
Alfuzosin—Headache—Methotrexate—systemic scleroderma	0.000417	0.000417	CcSEcCtD
Alfuzosin—Nausea—Methotrexate—systemic scleroderma	0.000395	0.000395	CcSEcCtD
